Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

05_02 Neuroendocrine Tumors

27:51
 
Share
 

Manage episode 480300955 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

1. Nomenclature, unique considerations

2. Secretory Syndromes

3. Somatostatin directed therapy

4. Peptide Receptor Radionucleotide Therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1–10

1. Kunz PL et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/

2. Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6

3. Strosberg J et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/

4. Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/

5. Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6. Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers

7. Pieterman CRC , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468

8. NANETS. Accessed May 1, 2025. https://nanets.net/

9. Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612,

10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

50 episodes

Artwork
iconShare
 
Manage episode 480300955 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

1. Nomenclature, unique considerations

2. Secretory Syndromes

3. Somatostatin directed therapy

4. Peptide Receptor Radionucleotide Therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1–10

1. Kunz PL et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/

2. Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6

3. Strosberg J et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/

4. Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/

5. Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6. Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers

7. Pieterman CRC , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468

8. NANETS. Accessed May 1, 2025. https://nanets.net/

9. Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612,

10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

50 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play